....i totally agree Werble, it looks like the requisitioners haven’t managed PVD well at all, whereas FTT produced such a good, well designed trial that it showed the technology to be not much more effective than the standard care (the trial was sensitive to small changes of inflection). It’s different to significant company funds allegedly going into into directors fees and expenses instead of actual company business (as outlined in FTTs recent Shareholder statement).
It will be a devastating blow to FTTs shareholders if the requisitioners were allowed to succeed.
justaguess
FTT Price at posting:
0.4¢ Sentiment: Buy Disclosure: Not Held
